The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 55 | 110.3x | 20.1x | Near average | |
Growth | 64 | 12.2% | 5.6% | Near average | |
Quality | 45 | 1.0% | 7.6% | Near average | |
Safety | 77 | -5.1x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Organogenesis Holdings Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Organogenesis Holdings Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analyst expectations for ORGO stock have undergone a radical shift toward caution, with the average price target dropping by 55% to $3, down from $6.67 a week ago. This sharp decline resulted from a new analyst joining the coverage with low estimates, leading to the complete disappearance of dispersion, as analysts now unanimously agree on a unified price target of $3, reflecting a more conservative and clear view regarding the stock's fair value.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.